

Vaxxinova US is pleased to announce the latest addition to its vaccine portfolio with the first and only fully-licensed inactivated *E. coli* vaccine in the U.S. poultry market – Vaxxon® SRP® E.coli-SE. This product, using innovative SRP Technology, is a combination *E. coli* and *Salmonella* Enteritidis vaccine for long-lived birds. This vaccine was developed to reduce mortality related to *E. coli* infection and reduction of *Salmonella* Enteritidis colonization in the reproductive tract, internal organs and intestinal tract.

This combination product is easily implemented into current vaccination programs. According to Dr. Dan Domingo, Technical Services Veterinarian, “A lot of producers are currently using an inactivated *Salmonella* Enteritidis vaccine in their program. By using this combination product, our customers will not have to add another injection to their program in order to add *E. coli* protection, they just replace what they are currently using for SE.”

Please reach out to account manager [jay.halliday@vaxxinova.com](mailto:jay.halliday@vaxxinova.com) or (320) 220-3009 for more information.

Vaxxinova US is the inventor of SRP Technology, successfully developing, manufacturing, and marketing a broad portfolio of USDA licensed biologics for livestock and poultry based on the SRP platform. With the recent acquisition of Newport Laboratories, Vaxxinova US is now a leading custom vaccine manufacturer – leveraging SRP Technology, plus cutting-edge diagnostics from Newport Labs and novel manufacturing technologies to “fill gaps” in health concerns for livestock and poultry.